DesignMedix, Inc.

DesignMedix develops impactful disease cures that overcome drug resistance, one of the top threats to human health. DesignMedix has developed a novel malaria cure that is ready for human trials. The drug could contribute to reducing the over 400,000 deaths yearly in a disease where drug resistance is on the rise. If approved by the FDA, the DesignMedix malaria drug would receive a tradable Priority Review Voucher; recent voucher sales have ranged from $125M to $350M.

Back to Companies

Sandra Shotwell
Chief Executive Officer